Oppenheimer feels ‘a lot better’ about Ideaya’s darovasertib plan after talks

Oppenheimer analyst Matthew Biegler noted that Ideaya management shared its latest thinking on the design of darovasertib’s Phase 3 trial in metastatic uveal melanoma, or MUM, at the JPMorgan healthcare conference and admits that if he had been told two weeks ago that the company was leaning toward a randomized trial exclusively in HLA-negative patients that he "would have called that a worst case scenario." However, after having spoke with management he now feels "a lot better about the plan," which he thinks gives darovasertib "the best chance of success and a path of least resistance to the market." Biegler has an Outperform rating on Ideaya shares.